The future management of comorbidities is expected to be driven by rapid advancements in technology, deeper biological insights, and the development of integrated healthcare models. As the burden of m

The gap

Consensus across the literature

Supporting evidence — 3 representative gaps

• Smart Polymers in Pharmaceutical Sciences: Stimuli-Responsive Systems for Targeted Drug Release (2026) · doi

  The evolution of smart polymer systems is moving rapidly from proof-of-concept lab studies to real-world biomedical applications, driven by cross-disciplinary innovation in materials science, biotechnology, and data intelligence. The next generation of smart polymers goes beyond single- trigger responses. Logic-based systems are being engineered to react to combinations of physiological signals—such as pH, temperature, enzymes, or redox gradients—allowing precise “AND/OR” gate-style control over drug release 85. This mimics the body’s own regulatory mechanisms, opening doors to more personalized and adaptive therapies. Artificial intelligence (AI) and machine learning are set to become core design tools for smart polymer development. Predictive modeling enables rapid optimization of polymer composition, crosslinking density, and stimulus-response kinetics 86. This shortens development timelines, reduces trial-and-error experimentation, and guides formulation toward clinically relevant endpoints. Smart hydrogels are transforming tissue engineering and regenerative medicine. By responding to cellular activity or microenvironmental cues, they can release growth factors and bioactive molecules in situ, creating dynamic scaffolds that support tissue growth, repair, and vascularization. 3D bioprinting technologies further enable customizable architectures for patient-specific implants 87. The focus of translational research is shifting toward long-acting injectables, implantable depots, and stimulus-sensitive devices. Early-stage human trials are already underway for smart insulin delivery systems, tumor-targeted nanocarriers, and adaptive wound dressings. Regulatory engagement, manufacturing scale-up, and robust safety profiling will be key to bridging the gap from bench to bedside 88.

  Keywords: smart polymer systems intelligence release regulatory adaptive development stimulus toward tissue growth evolution moving rapidly
• Recent Advancements in the Management and Treatment of Comorbidities: A Review (2026) · doi

  The future management of comorbidities is expected to be driven by rapid advancements in technology, deeper biological insights, and the development of integrated healthcare models. As the burden of multimorbidity continues to rise globally, there is a growing need for innovative strategies that can address the complexity of multiple coexisting conditions in a more precise, efficient, and patient- centered manner. 9.1 Emerging Technologies to revolutionize Emerging technologies such as artificial intelligence, machine learning, nanotechnology, and robotics are expected the management of comorbidities. AI-driven predictive models can enable early detection of disease progression and facilitate personalized treatment planning [64]. Nanotechnology-based systems are being developed for highly targeted drug delivery, allowing simultaneous treatment of multiple disease pathways with improved precision and reduced toxicity [65]. Robotics and automation in healthcare, including robotic surgery and automated drug dispensing systems, are enhancing treatment accuracy and INTERNATIONAL JOURNAL OF MEDICAL AND PHARMACEUTICAL SCIENCES 386

  Keywords: treatment management comorbidities expected driven healthcare models multiple emerging technologies nanotechnology robotics disease systems drug
• Integrated Transdermal Therapeutic Systems: Technologies, Applications and Challenges (2026) · doi

  healthcare customized The future of integrated transdermal therapeutic systems requires creation of intelligent, adaptable, and platforms. Enhancement of patient comfort, scalability and device performance can be expected from such systems by developments in biomaterials, additive manufacturing, and nanotechnology. electronics flexible drug Artificial Intelligence (AI) and Machine Learning (ML) have the potential to revolutionize future integrated systems. AI-assisted systems can enable predictive current dosing, modulation, real-time physiological monitoring and closed-loop therapeutic control based on patient-specific responses. ML algorithms can evaluate physiological signs and optimize drug delivery, paving way to customized treatment plans. adaptive In the future, wearable theranostic systems may combine biosensors, wireless communication modules, cloud computing and AI-driven analytics printing to provide remote healthcare management and precision medicine, resulting in smart systems treatment with autonomous diagnosis and 3D capabilities. additive and technologies are capable of manufacturing streamlining the rapid prototyping and customized manufacture of transdermal devices with unique geometries. Further, sustainability and long-term usability can be improved by use of self-powered systems and biodegradable materials.

  Keywords: systems customized future healthcare integrated transdermal therapeutic patient additive manufacturing drug physiological treatment requires creation